Molecular heterogeneity in hepatocellular carcinoma

References

• Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391(10126), 1163–1173 (2018).
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (resorce): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064), 56–66 (2017).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379(1), 54–63 (2018).
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma (checkmate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088), 2492–2502 (2017).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (keynote-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 19(7), 940–952 (2018).
   PubMed Web of Science ®Google Scholar
• Parikh ND, Singal AG, Hutton DW. Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma. Cancer 123(19), 3725–3731 (2017).
   PubMed Web of Science ®Google Scholar
• Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat. Oncol. 2(4), 371–379 (2015).
   PubMedGoogle Scholar
• Cancer Genome Atlas Research Network. Electronic address wbe, cancer genome atlas research n. comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169(7), 1327–1341 e1323 (2017).
   PubMed Web of Science ®Google Scholar
• Hagel M, Miduturu C, Sheets M et al. First selective small molecule inhibitor of fgfr4 for the treatment of hepatocellular carcinomas with an activated fgfr4 signaling pathway. Cancer discov. 5(4), 424–437 (2015).
   PubMed Web of Science ®Google Scholar
• Rimassa L, Assenat E, Peck-Radosavljevic M et al. Tivantinib for second-line treatment of met-high, advanced hepatocellular carcinoma (metiv-hcc): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol. 19(5), 682–693 (2018).
   PubMed Web of Science ®Google Scholar
• Rebouissou S, La Bella T, Rekik S et al. Proliferation markers are associated with met expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro. Clin. Cancer Res. 23(15), 4364–4375 (2017).
   PubMed Web of Science ®Google Scholar
• Zhu AX, Baron AD, Malfertheiner P et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of reach trial results by child-pugh score. JAMA Oncol. 3(2), 235–243 (2016).
   Web of Science ®Google Scholar
• Hoshida Y, Nijman SM, Kobayashi M et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69(18), 7385–7392 (2009).
   PubMed Web of Science ®Google Scholar
• Tan PS, Nakagawa S, Goossens N et al. Clinicopathological indices to predict hepatocellular carcinoma molecular classification. Liver Int. 36(1), 108–118 (2016).
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology doi: 10.1002/hep.29904 (2018) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Chaisaingmongkol J, Budhu A, Dang H et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32(1), 57–70 e53 (2017).
   PubMed Web of Science ®Google Scholar
• Hirschfield H, Bian CB, Higashi T et al. In vitro modeling of hepatocellular carcinoma molecular subtypes for anti-cancer drug assessment. Exp. Mol. Med. 50(1), e419 (2018).
   PubMedGoogle Scholar
• Finn RS, Aleshin A, Dering J et al. Molecular subtype and response to dasatinib, an src/abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 57(5), 1838–1846 (2013).
   PubMed Web of Science ®Google Scholar
• Gao Q, Wang ZC, Duan M et al. Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. Gastroenterology 152(1), 232–242 e234 (2017).
   PubMed Web of Science ®Google Scholar
• Fong ELS, Toh TB, Lin QXX et al. Generation of matched patient-derived xenograft in vitro-in vivo models using 3d macroporous hydrogels for the study of liver cancer. Biomaterials 159, 229–240 (2018).
   PubMed Web of Science ®Google Scholar
• Schmidt B, Wei L, Deperalta DK et al. Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. Int. J. Cancer 138(6), 1494–1505 (2016).
   PubMed Web of Science ®Google Scholar
• Calderaro J, Couchy G, Imbeaud S et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J. Hepatol. 67(4), 727–738 (2017).
   PubMed Web of Science ®Google Scholar
• Zhai W, Lim TK, Zhang T et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun. 8, 4565 (2017).
   PubMed Web of Science ®Google Scholar
• Huang A, Zhao X, Yang XR et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. J. Hepatol. 67(2), 293–301 (2017).
   PubMed Web of Science ®Google Scholar
• Sun YF, Guo W, Xu Y et al. Circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma. Clin. Cancer Res. 24(3), 547–559 (2018).
   PubMed Web of Science ®Google Scholar
• Hectors SJ, Wagner M, Bane O et al. Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci. Rep. 7(1), 2452 (2017).
   PubMedGoogle Scholar
• Mule S, Thiefin G, Costentin C et al. Advanced hepatocellular carcinoma: Pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with sorafenib. Radiology 288(2), 445–455 (2018).
   PubMed Web of Science ®Google Scholar